Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
The recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the phase III OnTarget trial indicate that crofelemer (Mytesi, Fulyzaq) achieved statistical significance in this subgroup.
